
    
      Hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) is a severe disease
      with high mortality. In this study, the investigators intend to assess the efficacy and
      safety of Thymosin-Î±1 in patients with HBV-related Acute-on-chronic liver failure.
    
  